The human body needs a key protein called survival motor neuron, or SMN, for our muscles to function properly.
People with SMA have low levels of this protein, causing muscles to break down.
*When studied in animals, this protein was distributed throughout the body.
Within 4 weeks of treatment with Evrysdi, SMN protein levels in the blood approximately doubled, and they were maintained for Types 1, 2, and 3 SMA throughout 2 years of the pivotal studies†
†No data available in presymptomatic SMA (under 2 months).
Hear community perspectives on Evrysdi
Información de prescripción de Evrysdi® (risdiplam). Genentech, Inc.
Información de prescripción de Evrysdi® (risdiplam). Genentech, Inc.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.